BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 15367686)

  • 1. Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway.
    Guo S; Sonenshein GE
    Mol Cell Biol; 2004 Oct; 24(19):8681-90. PubMed ID: 15367686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of FOXO3a by the green tea polyphenol epigallocatechin-3-gallate induces estrogen receptor alpha expression reversing invasive phenotype of breast cancer cells.
    Belguise K; Guo S; Sonenshein GE
    Cancer Res; 2007 Jun; 67(12):5763-70. PubMed ID: 17575143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
    Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
    Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN.
    Pianetti S; Arsura M; Romieu-Mourez R; Coffey RJ; Sonenshein GE
    Oncogene; 2001 Mar; 20(11):1287-99. PubMed ID: 11313873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K.
    Sun M; Paciga JE; Feldman RI; Yuan Z; Coppola D; Lu YY; Shelley SA; Nicosia SV; Cheng JQ
    Cancer Res; 2001 Aug; 61(16):5985-91. PubMed ID: 11507039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway.
    Stoica GE; Franke TF; Moroni M; Mueller S; Morgan E; Iann MC; Winder AD; Reiter R; Wellstein A; Martin MB; Stoica A
    Oncogene; 2003 Sep; 22(39):7998-8011. PubMed ID: 12970748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estradiol rapidly activates Akt via the ErbB2 signaling pathway.
    Stoica GE; Franke TF; Wellstein A; Czubayko F; List HJ; Reiter R; Morgan E; Martin MB; Stoica A
    Mol Endocrinol; 2003 May; 17(5):818-30. PubMed ID: 12554767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen receptor alpha binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor gamma signaling in breast cancer cells.
    Bonofiglio D; Gabriele S; Aquila S; Catalano S; Gentile M; Middea E; Giordano F; Andò S
    Clin Cancer Res; 2005 Sep; 11(17):6139-47. PubMed ID: 16144913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a).
    Brunet A; Park J; Tran H; Hu LS; Hemmings BA; Greenberg ME
    Mol Cell Biol; 2001 Feb; 21(3):952-65. PubMed ID: 11154281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: relevance in cell proliferation.
    Pozo-Guisado E; Lorenzo-Benayas MJ; Fernández-Salguero PM
    Int J Cancer; 2004 Mar; 109(2):167-73. PubMed ID: 14750165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells.
    Oh AS; Lorant LA; Holloway JN; Miller DL; Kern FG; El-Ashry D
    Mol Endocrinol; 2001 Aug; 15(8):1344-59. PubMed ID: 11463858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen-related receptor alpha1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway.
    Ariazi EA; Kraus RJ; Farrell ML; Jordan VC; Mertz JE
    Mol Cancer Res; 2007 Jan; 5(1):71-85. PubMed ID: 17259347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The estrogen receptor α is the key regulator of the bifunctional role of FoxO3a transcription factor in breast cancer motility and invasiveness.
    Sisci D; Maris P; Cesario MG; Anselmo W; Coroniti R; Trombino GE; Romeo F; Ferraro A; Lanzino M; Aquila S; Maggiolini M; Mauro L; Morelli C; Andò S
    Cell Cycle; 2013 Nov; 12(21):3405-20. PubMed ID: 24047697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Forkhead Box Transcription Factor (FOXO3a) mediates the cytotoxic effect of vernodalin in vitro and inhibits the breast tumor growth in vivo.
    Ananda Sadagopan SK; Mohebali N; Looi CY; Hasanpourghadi M; Pandurangan AK; Arya A; Karimian H; Mustafa MR
    J Exp Clin Cancer Res; 2015 Dec; 34():147. PubMed ID: 26643256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
    Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
    Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylation of FOXO3a by PI3K/Akt pathway in HK-2 renal proximal tubular epithelial cells exposed to cadmium.
    Fujiki K; Inamura H; Matsuoka M
    Arch Toxicol; 2013 Dec; 87(12):2119-27. PubMed ID: 23673518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGF-2 Transcriptionally Down-Regulates the Expression of BNIP3L via PI3K/Akt/FoxO3a Signaling and Inhibits Necrosis and Mitochondrial Dysfunction Induced by High Concentrations of Hydrogen Peroxide in H9c2 Cells.
    Chen Q; Chen X; Han C; Wang Y; Huang T; Du Y; Dong Z
    Cell Physiol Biochem; 2016; 40(6):1678-1691. PubMed ID: 28006775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
    Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
    Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer.
    Cui X; Zhang P; Deng W; Oesterreich S; Lu Y; Mills GB; Lee AV
    Mol Endocrinol; 2003 Apr; 17(4):575-88. PubMed ID: 12554765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.